Neurocrine Biosciences
NBIX
NBIX
417 hedge funds and large institutions have $8.63B invested in Neurocrine Biosciences in 2020 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 188 increasing their positions, 109 reducing their positions, and 68 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
417
Holders Change
–
Holders Change %
0%
% of All Funds
8.44%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.14%
New
70
Increased
188
Reduced
109
Closed
68
Calls
$40.5M
Puts
$136M
Net Calls
-$95.1M
Net Calls Change
-$101M
Top Buyers
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$73.8M |
| 2 |
Renaissance Technologies
New York
|
+$63.9M |
| 3 |
HM
HealthCor Management
New York
|
+$54.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.4M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$27.5M |
Top Sellers
| 1 |
Capital International Investors
Los Angeles,
California
|
-$175M |
| 2 |
BlackRock
New York
|
-$66.5M |
| 3 |
PA
Perceptive Advisors
New York
|
-$57M |
| 4 |
Jennison Associates
New York
|
-$41.7M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$37.8M |
